A Better Mouse Trap
Executive Summary
By their very nature, successful new technological approaches to large, unmet clinical needs--the Holy Grail for companies and their investors--have to offer something new, something that the existing gold standard didn't. But it is precisely that innovative approach that gives physician pause. New technology is often too slowly adopted. If drug-eluting stents catch on in great numbers,, they may revive the debates about the value of technology.
You may also be interested in...
Hijacking the Restenosis Market
Innovative device companies have always had to contend with the Sword of Damocles of unexpected technological obsolescence, but for would-be developers of interventional devices for the prevention of restenosis, the sword is dangling perilously close. In the RAVEL trial, a 238-patient clinical trial on a drug eluting stent, treated patients experienced 0% restenosis compared to 26% in the control group. Now, device developers with alternatives to stents reposition themselves to sustain businesses in the face of potentially shrinking target markets. Many argue that they will serve certain applications better than stents; others hope to work with drug-coated stents to enhance performance, many believe that economics will leave room for alternative approaches, and still others are getting out of the coronary business entirely.
Indoco Builds On Recent Growth With Acquisition In US
Indoco says it has marked a major milestone with a $4m deal to take a controlling stake in US firm Florida Pharmaceutical Products, strengthening the Indian company’s position in the US market.
ChatGPT Unleashed: Generative AI Use Cases Taking Off In Pharma
As generative AI and its star avatar, ChatGPT, take the world by storm, pharma is seeing traction for use cases around smarter pharmacovigilance and commercial marketing content development, among others. Senior executives from Indegene discuss this and more in an interview with Scrip.